Read by QxMD icon Read

Heart failure diabetes mellitus

Mohammed Al-Jarallah, Rajesh Rajan, Ibrahim Al-Zakwani, Raja Dashti, Bassam Bulbanat, Kadhim Sulaiman, Alawi A Alsheikh-Ali, Prashanth Panduranga, Khalid F AlHabib, Jassim Al Suwaidi, Wael Al-Mahmeed, Hussam AlFaleh, Abdelfatah Elasfar, Ahmed Al-Motarreb, Mustafa Ridha, Nooshin Bazargani, Nidal Asaad, Haitham Amin
AIMS: This study aims to evaluate the incidence and impact of cardiorenal anaemia syndrome (CRAS) on all-cause mortality in acute heart failure (AHF) patients stratified by left ventricular ejection fraction (LVEF) status in the Middle East. METHODS AND RESULTS: Data were analysed from 4934 consecutive patients admitted to 47 hospitals in seven Middle Eastern countries (Saudi Arabia, Oman, Yemen, Kuwait, United Arab Emirates, Qatar, and Bahrain) with AHF from February to November 2012...
October 12, 2018: ESC Heart Failure
Sadeer G Al-Kindi, Jassim Al-Suwaidi, Amin Jayyousi, Guilherme H Oliveira, Charbel Abi Khalil
Diabetes mellitus (DM) is associated with increased mortality in advanced heart failure and in patients undergoing cardiac surgery. However, its impact on outcomes in patients supported with left ventricular assist devices (LVAD) is not well established. We queried the United Network for Organ Sharing (UNOS) for all adults listed for heart transplantation and bridged with continuous-flow LVAD in the United States from 2000 to 2015. We compared the pre- and post-transplant mortality of patients with and without DM...
October 9, 2018: ASAIO Journal: a Peer-reviewed Journal of the American Society for Artificial Internal Organs
A Reshad Garan, Waqas A Malick, Marlena Habal, Veli K Topkara, Justin Fried, Amirali Masoumi, Aws K Hasan, Dimitri Karmpaliotis, Ajay Kirtane, Melana Yuzefpolskaya, Maryjane Farr, Yoshifumi Naka, Dan Burkhoff, Paolo C Colombo, Paul Kurlansky, Hiroo Takayama, Koji Takeda
Chronic systolic heart failure (HF) with acute decompensation can result in cardiogenic shock (CS) requiring short-term mechanical circulatory support. We sought to identify predictors of survival for acute decompensated HF (ADHF) patients requiring veno-arterial extracorporeal membrane oxygenation (VA-ECMO). Patients >18 years old treated at our institution with VA-ECMO from 2009 to 2018 for ADHF with CS were studied. Demographic, hemodynamic, and echocardiographic data were collected. The primary outcome was survival to discharge...
October 9, 2018: ASAIO Journal: a Peer-reviewed Journal of the American Society for Artificial Internal Organs
Petros Kikas, George Chalikias, Dimitrios Tziakas
Sphingomyelin (SM) is a type of sphingolipid found within plasma, cellular membranes and plasma lipoproteins. Here we highlight the basic biochemical features of SMs and their role in biological membranes. We further discuss evidence of the association between SM and cardiovascular diseases such as atherosclerosis, valvular disease, heart failure and diabetes mellitus.
August 2018: European Cardiology
Maria Isabel Smáradóttir, Sergiu-Bogdan Catrina, Kerstin Brismar, Anna Norhammar, Viveca Gyberg, Linda G Mellbin
PURPOSE: Copeptin and insulin-like growth factor binding protein-1 analysed at admission for a myocardial infarction in patients with type 2 diabetes mellitus predicts cardiovascular events. The present aim was to study the association between copeptin and insulin-like growth factor binding protein-1, the development of the levels over time, and if the predictive value remained when measured at hospital discharge and 3 months thereafter. METHODS: Copeptin and insulin-like growth factor binding protein-1 were analysed in patients (median age = 70, male = 68%) with type 2 diabetes mellitus + myocardial infarction at admission (n = 393), discharge (n = 309) and 3 months later (n = 288)...
October 11, 2018: Diabetes & Vascular Disease Research
Ayhan Şahin, Onur Baran
Reports on pacemaker placement/relocation surgery under pectoralis nerve block are limited. We herein report a case involving a 74-year-old woman with an infected cardiac pacemaker generator who underwent pacemaker relocation surgery under an ultrasound-guided pectoralis nerve block. On preoperative evaluation, she had congestive heart failure, type 2 diabetes mellitus, and a pacer-dependent heart rhythm. She was considered to be at high risk for general anesthesia. Thus, an ultrasound-guided pectoralis nerve block was planned...
October 5, 2018: A&A practice
Fumitaka Soga, Hidekazu Tanaka, Kazuhiro Tatsumi, Yasuhide Mochizuki, Hiroyuki Sano, Hiromi Toki, Kensuke Matsumoto, Junya Shite, Hideyuki Takaoka, Tomofumi Doi, Ken-Ichi Hirata
BACKGROUND: The objective of this study was to investigate the impact of sodium glucose cotransporter type 2 (SGLT2) inhibitors on left ventricular (LV) diastolic function of type 2 diabetes mellitus (T2DM) patients with heart failure (HF). METHODS: This trial was a prospective multicenter study of 58 T2DM patients with stable HF at five institutions in Japan. Patients who had been taking at least one antidiabetic drugs other than SGLT2 inhibitors started the administration of 5 mg/day of dapagliflozin...
October 8, 2018: Cardiovascular Diabetology
Nicolas Lamblin, Thibaud Meurice, Olivier Tricot, Pascal de Groote, Gilles Lemesle, Christophe Bauters
BACKGROUND: We lack recent data on the incidence, correlates, and prognosis associated with heart failure (HF) development in patients with stable coronary artery disease (CAD). Here, we analyzed HF development in a contemporary population of outpatients with stable CAD. METHODS AND RESULTS: Of 4184 unselected outpatients with stable CAD (i.e., myocardial infarction [MI] and/or coronary revascularization >1 year prior) included in the multicenter CORONOR registry, we identified 3871 patients with no history of hospitalization for HF at inclusion, and followed 3785 (98%) for 5 years...
October 5, 2018: Journal of Cardiac Failure
Pei-Yu Liu, Chien-Lin Chen, Min-Chien Yu, Yu-Lin Ko, Shun-Yi Hsu, Hsin-Hua Chou, Kuan-Hung Yeh, De-Min Duan, Ming-Hsin Chen, Jeng-Feng Lin
OBJECTIVES: In patients with ST-elevation myocardial infarction (STEMI), it is not clear whether low-dose renin-angiotensin system inhibitors and beta-blockers can result in the same benefits achievable with higher target doses. This observational study aims to investigate whether higher doses of angiotensin converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARB) and beta-blockers can improve outcomes in patients with STEMI. METHODS: We recorded daily doses of ACEI, ARB, and beta-blockers in 331 patients with STEMI...
October 8, 2018: Acta Clinica Belgica
Amr Salama, Abdullah Abdullah, Abdul Wahab, George Eigbire, Ryan Hoefen, Ruth Kouides, Nathan Ritter, Hanna Mieszczanska, Richard Alweis
BACKGROUND: Obstructive sleep apnea (OSA) is a known independent risk factor for a multiple cardiovascular morbidities and mortality. The association of OSA and ventricular arrhythmias is less well understood. The aim of this analysis to study the relationship between OSA and ventricular tachyarrhythmias. HYPOTHESIS: OSA is associated with increased ventricular arrhythmias METHODS: Data from the National Inpatient Sample (NIS) 2012 - 2014, were reviewed. Discharges associated with OSA were identified as the target population using the relevant ICD-9-CM codes...
October 7, 2018: Clinical Cardiology
Kwong-Man Ng, Yee-Man Lau, Vidhu Dhandhania, Zhu-Jun Cai, Yee-Ki Lee, Wing-Hon Lai, Hung-Fat Tse, Chung-Wah Siu
Empagliflozin, a sodium-glucose co-transporter (SGLT) inhibitor, reduces heart failure and sudden cardiac death but the underlying mechanisms remain elusive. In cardiomyocytes, SGLT1 and SGLT2 expression is upregulated in diabetes mellitus, heart failure, and myocardial infarction. We hypothesise that empagliflozin exerts direct effects on cardiomyocytes that attenuate diabetic cardiomyopathy. To test this hypothesis, cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs) were used to test the potential effects of empagliflozin on neutralization of cardiac dysfunction induced by diabetic-like cultures...
October 5, 2018: Scientific Reports
Christopher P Cannon, Darren K McGuire, Richard Pratley, Sam Dagogo-Jack, James Mancuso, Susan Huyck, Bernard Charbonnel, Weichung J Shih, Silvina Gallo, Urszula Masiukiewicz, Gregory Golm, Francesco Cosentino, Brett Lauring, Steven G Terra
BACKGROUND: Ertugliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), approved in the United States and European Union to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). The VERTIS cardiovascular (CV) outcomes trial (NCT01986881) has a primary objective to demonstrate non-inferiority of ertugliflozin versus placebo on major adverse CV events: time to the first event of CV death, nonfatal myocardial infarction, or nonfatal stroke. Secondary objectives are to demonstrate superiority of ertugliflozin versus placebo on time to: 1) the composite outcome of CV death or hospitalization for heart failure (HF); 2) CV death; and 3) the composite outcome of renal death, dialysis/transplant, or doubling of serum creatinine from baseline...
September 5, 2018: American Heart Journal
Jonathan D Newman, Anish K Vani, Jose O Aleman, Howard S Weintraub, Jeffrey S Berger, Arthur Z Schwartzbard
Type 2 diabetes mellitus (T2D) is a major risk factor for cardiovascular disease (CVD), the most common cause of death in T2D. Despite improved risk factor control, however, adults with T2D continue to experience substantial excess CVD risk. Until recently, however, improved glycemic control has not been associated with robust macrovascular benefit. The advent of 2 new classes of antihyperglycemic agents, the sodium-glucose cotransporter-2 inhibitors and the glucagon-like peptide-1 receptor agonists, and their respective large cardiovascular outcome trials, has led to a paradigm shift in how cardiologists and heath care practitioners conceptualize T2D treatment...
October 9, 2018: Journal of the American College of Cardiology
Robbert J de Winter, Jaya Chandrasekhar, Deborah N Kalkman, Melissa B Aquino, Pier Woudstra, Marcel A Beijk, Samantha Sartori, Usman Baber, Jan G Tijssen, Karel T Koch, George D Dangas, Antonio Colombo, Roxana Mehran
OBJECTIVES: The aim of this study was to evaluate 1-year clinical safety and efficacy of the dual-therapy COMBO stent in a large, all-comers patient-level pooled cohort. BACKGROUND: The COMBO stent (OrbusNeich Medical, Fort Lauderdale, Florida) is a novel stent with abluminal sirolimus elution from a biodegradable polymer and a luminal pro-healing anti-CD34+ antibody layer, which attracts circulating endothelial progenitor cells. These endothelial progenitor cells can quickly mature into normal endothelium, providing rapid endothelialization...
October 8, 2018: JACC. Cardiovascular Interventions
Andrea Hetzenecker, Christoph Fisser, Stefan Stadler, Michael Arzt
In 2017 the German Sleep Society (Deutsche Gesellschaft für Schlafforschung und Schlafmedizin, DGSM) published the new S3 guideline "Nonrestorative Sleep/Sleep Disorders, chapter "Sleep-Related Breathing Disorders in Adults".Sleep apnea contributes to an increased morbidity and mortality in patients with cardiovascular diseases, e. g. coronary heart disease, heart failure and diabetes mellitus and is associated with an increased perioperative risk. It is also an important comorbidity in respiratory, neurologic and oncologic diseases...
October 2018: Deutsche Medizinische Wochenschrift
Zoltán Papp, Tamás Radovits, Walter J Paulus, Nazha Hamdani, Petar M Seferović
No abstract text is available yet for this article.
October 2, 2018: European Journal of Heart Failure
Martin Høhrmann Hangaard, Peter Rossing, Jan Skov Jensen, Magnus Thorsten Jensen
There are 320,000 diabetes patients in Denmark. Heart failure (HF) is a major cardiovascular complication to diabetes mellitus with increasing prevalence. HF occurs 2-4 times more frequently in diabetes patients, but patients may go undiagnosed for years. Diabetes patients typically suffer from diastolic dysfunction caused by myocardial hyper-trophy and "stiffness" of the left ventricle. This frequent finding has prompted the term "diabetic cardiomyopathy". Echocardiography is a key examination in diagnosing HF and may be warranted to a greater degree in diabetes patients at particular risk...
October 1, 2018: Ugeskrift for Laeger
Prashanthi Vemuri, Timothy G Lesnick, Scott A Przybelski, Jonathan Graff-Radford, Robert I Reid, Val J Lowe, Samantha M Zuk, Matthew L Senjem, Christopher G Schwarz, Jeffrey L Gunter, Kejal Kantarci, Mary M Machulda, Michelle M Mielke, Ronald C Petersen, David S Knopman, Clifford R Jack
OBJECTIVE: Recent availability of amyloid and tau PET has provided us with a unique opportunity to measure the association of systemic vascular health with brain health after accounting for the impact of AD pathologies. We wanted to quantify early cerebrovascular health related MRI brain measures (structure, perfusion, microstructural integrity) and evaluate their utility as a biomarker for cerebrovascular health. METHODS: We used two independent samples (Discovery: n= 390; Validation: n=1035) of individuals, aged ≥60 years, along the cognitive continuum with imaging from the population-based sample of Mayo Clinic Study of Aging...
September 28, 2018: Annals of Neurology
Ilia Davarashvili, Moshe Rav Acha, Michael Glikson, Rivka Farkash, Benjamin Mazouz, Adi Butnaru, Tal Hasin
Acute pulmonary congestion (APC) may occur within hours after electrical cardioversion of atrial fibrillation (AF). There is scarce data about its incidence, risk factors, and the outcome. In the present study, data of consecutive patients admitted for first electrical cardioversion for AF between 2007 and 2016 were retrospectively reviewed. APC within the 48hours following cardioversion was defined as dyspnea and at least one of the following: drop in saturation to <90%, administration of intravenous diuretic or an emergent chest X-ray with new pulmonary congestion...
August 21, 2018: American Journal of Cardiology
Satoshi Ida, Ryutaro Kaneko, Kazuya Murata
BACKGROUND: We used a network meta-analysis of randomized controlled trials (RCTs) to comparatively examine the effects of oral antidiabetic drugs (OADs) on left ventricular mass (LVM) in patients with type 2 diabetes. METHODS: Document searches were implemented using Medline, Cochrane Controlled Trials Registry, and We decided to include RCTs that evaluated the impact of LVM using the administration of OADs to patients with type 2 diabetes. The outcome evaluations used standardized mean difference (SMD) and 95% confidence intervals (CIs)...
September 27, 2018: Cardiovascular Diabetology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"